Zentalis Pharma shakes up plans for Phase III in ovarian cancer: Zentalis announced Monday that it is no longer planning to test its lead candidate, azenosertib, in combination with chemotherapy in second-line platinum-sensitive ovarian cancer (PSOC) patients. The Phase III study was expected to start in the first quarter of next year. Instead, the company plans to test the wee1 inhibitor as a first-line maintenance treatment for PSOC, pushing back the timeline for beginning a Phase III trial into 2025. Zentalis also shared updated results from a Phase I study in platinum-resistant ovarian cancer. The biotech is currently running a Phase II trial for which it plans to share topline data in 2025. Zentalis {ZNTL} shares fell over 20% after markets opened Monday. — Lei Lei Wu
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.